{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:52Z","timestamp":1783930372005,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04098-4","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:34:45Z","timestamp":1781073285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of NEPA for prevention of chemotherapy induced nausea and vomiting in head and neck cancer patients receiving cisplatin-based chemotherapy"],"prefix":"10.1007","volume":"82","author":[{"given":"Tzer-Zen","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Chien","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Feng","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-An","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Heng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Che","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4098_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260\u20131267","journal-title":"Ann Oncol"},{"key":"4098_CR2","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2010.34.2816","volume":"29","author":"DK Mayer","year":"2011","unstructured":"Mayer DK et al (2011) Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 29:2683\u20132688","journal-title":"J Clin Oncol"},{"key":"4098_CR3","first-page":"585","volume":"30","author":"B Loteta","year":"2022","unstructured":"Loteta B et al (2022) Netupitant\/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. Support Care Cancer 30:585\u2013591","journal-title":"Support Care Cancer"},{"key":"4098_CR4","doi-asserted-by":"crossref","unstructured":"Lorusso D et al (2017) Patients\u2019 perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl) 26:e12618","DOI":"10.1111\/ecc.12618"},{"key":"4098_CR5","first-page":"100278","volume":"26","author":"KWR Gupta","year":"2021","unstructured":"Gupta KWR, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 26:100278","journal-title":"Cancer Treat Res Commun"},{"key":"4098_CR6","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073\u2013e1082","journal-title":"Oncologist"},{"key":"4098_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K et al (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197\u2013202","journal-title":"Eur J Pharmacol"},{"key":"4098_CR8","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"EPA Basch","year":"2011","unstructured":"Basch EPA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"key":"4098_CR9","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ et al (2017) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261","journal-title":"J Clin Oncol"},{"key":"4098_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A et al (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: Results from a European prospective observational study. J Pain Symptom Manage 47:839\u2013848","journal-title":"J Pain Symptom Manage"},{"key":"4098_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2013.08.049","volume":"722","author":"C Rojas","year":"2014","unstructured":"Rojas C et al (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26\u201337","journal-title":"Eur J Pharmacol"},{"key":"4098_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/17425255.2024.2367593","volume":"20","author":"A Orhan","year":"2024","unstructured":"Orhan A et al (2024) Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Metab Toxicol 20:473\u2013489","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4098_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346","journal-title":"Ann Oncol"},{"key":"4098_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"MRH Aapro","year":"2014","unstructured":"Aapro MRH, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333","journal-title":"Ann Oncol"},{"key":"4098_CR15","doi-asserted-by":"publisher","first-page":"103143","DOI":"10.1016\/j.critrevonc.2020.103143","volume":"157","author":"Matti Aapro","year":"2021","unstructured":"Matti Aapro et al (2021) Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Reviews Oncol \/ Hematol 157:103143","journal-title":"Crit Reviews Oncol \/ Hematol"},{"key":"4098_CR16","first-page":"9307","volume":"30","author":"Jonas","year":"2022","unstructured":"Jonas, Nilsson et al (2022) Cost\u2013effectiveness analysis of NEPA, a fixed\u2013dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy\u2013induced nausea and vomiting: an international perspective. Support Care Cancer 30:9307\u20139315","journal-title":"Support Care Cancer"},{"key":"4098_CR17","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1002\/cam4.3123","volume":"9","author":"C Jianhua","year":"2020","unstructured":"Jianhua C et al (2020) Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med 9:5134\u20135142","journal-title":"Cancer Med"},{"key":"4098_CR18","doi-asserted-by":"publisher","first-page":"15769","DOI":"10.1002\/cam4.6121","volume":"12","author":"L Zelek","year":"2023","unstructured":"Zelek L et al (2023) Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med 12:15769\u201315776","journal-title":"Cancer Med"},{"key":"4098_CR19","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2217\/fon-2021-0023","volume":"17","author":"RM Navari","year":"2021","unstructured":"Navari RM et al (2021) Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol 17:3027\u20133035","journal-title":"Future Oncol"},{"key":"4098_CR20","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1002\/onco.13888","volume":"26","author":"L Zelek","year":"2021","unstructured":"Zelek L et al (2021) A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Oncologist 26:e1870\u2013e1879","journal-title":"Oncologist"},{"key":"4098_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/fon-2022-0972","volume":"19","author":"W Nelson","year":"2023","unstructured":"Nelson W et al (2023) Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy. Future Oncol 19:29\u201336","journal-title":"Future Oncol"},{"key":"4098_CR22","doi-asserted-by":"crossref","unstructured":"Hesketh PJ et al (2015) A Review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:651879","DOI":"10.1155\/2015\/651879"},{"key":"4098_CR23","first-page":"155","volume":"9","author":"RM N","year":"2014","unstructured":"RM N (2014) Profile of netupitant\/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155\u2013161","journal-title":"Drug Des Devel Ther"},{"key":"4098_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12885-020-6707-9","volume":"20","author":"R Caputo","year":"2020","unstructured":"Caputo R et al (2020) Netupitant\/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. BMC Cancer 20:232","journal-title":"BMC Cancer"},{"key":"4098_CR25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41598-023-28464-9","volume":"13","author":"Luigi","year":"2023","unstructured":"Luigi, Celio et al (2023) Exploratory analysis of the effect of a dexamethasone\u2013sparing regimen for prophylaxis of cisplatin\u2013induced emesis on food intake (LUNG\u2013NEPA study). Sci Rep 13:1257","journal-title":"Sci Rep"},{"key":"4098_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Netupitant\/palonosetron: A review in chemotherapy-induced nausea and vomiting. Drugs 81:1331\u20131342","journal-title":"Drugs"},{"key":"4098_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00228-021-03157-2","volume":"77","author":"YC Hsu","year":"2021","unstructured":"Hsu YC et al (2021) Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol 77:1597\u20131609","journal-title":"Eur J Clin Pharmacol"},{"key":"4098_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s11684-025-1140-8","volume":"19","author":"H Zhu","year":"2025","unstructured":"Zhu H et al (2025) Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting. Front Med 19:600\u2013611","journal-title":"Front Med"},{"key":"4098_CR29","doi-asserted-by":"publisher","first-page":"oyae233","DOI":"10.1093\/oncolo\/oyae233","volume":"30","author":"WT Luo","year":"2025","unstructured":"Luo WT et al (2025) Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. Oncologist 30:oyae233","journal-title":"Oncologist"},{"key":"4098_CR30","first-page":"1309","volume":"27","author":"S Baron-Hay","year":"2019","unstructured":"Baron-Hay S et al (2019) Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 27:1309\u20131317","journal-title":"Support Care Cancer"},{"key":"4098_CR31","doi-asserted-by":"crossref","unstructured":"Kennedy SKF et al (2024) 2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 32:280","DOI":"10.1007\/s00520-024-08462-x"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04098-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:33Z","timestamp":1783929453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04098-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4098"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04098-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study was approved and conducted in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Board of E-Da Hospital (EMRP-111-119). The study design and conduct complied with all relevant local regulations regarding the use of human study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Due to the retrospective nature of the study, informed consents were waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}